Search
First Tracks Biotherapeutics Ord Shs
TRAXAdd to Watchlist
35.500USD
-1.160-3.16%
Market hours 09/24, 11:54（ET）
1.24BMarket Cap
0.00P/E TTM
TRAX Analyst Recommendation Trends
In the current month, TRAX has received 6 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. TRAX average Analyst price target in the last month is 72.500.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
3
3
2
2
2
0
0
0
6
6
6
5
4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9
9
8
7
6
0
0
0
Financial Forecasting
Based on analysts' estimates, TRAX EPS is projected to reach -0.915 in FY2026Q3, following reported EPS of -0.953 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
--
-0.52
-0.83
-0.91
-0.85
Actual
-4.78
-1.45
-0.95
--
--
Surprise
--
-178.32%
-14.62%
--
--
FAQs
What is First Tracks Biotherapeutics Ord Shs's expected revenue for the next quarter?
First Tracks Biotherapeutics Ord Shs's expected revenue is 4.45M.
How have First Tracks Biotherapeutics Ord ShsTRAX's recent earnings per share performed?
The market expectation was USD -0.95, while First Tracks Biotherapeutics Ord ShsTRAX's earnings per share (EPS) for the previous quarter was USD -1.45. EPS for the next quarter is expected at USD -0.85.
What is the analyst rating for First Tracks Biotherapeutics Ord Shs?
Based on the ratings of First Tracks Biotherapeutics Ord Shs's stock from 9 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.